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Abstract 
 
Introduction and Aim 
Hemophilia A is a bleeding disorder caused by an inherited deficiency of blood coagulation 
factor VIII (FVIII). FVIII functions as a cofactor to promote blood coagulation when activated 
by either thrombin or activated factor X (FXa). The resultant activated factor VIII (FVIIIa) 
binds to both factor IX (FIX) and factor X (FX) which have serine protease activity when 
activated. FX is a substrate for activated factor IX (FIXa) protease. The binding properties of 
FVIII to FIXa and FX contribute to FVIII’s cofactor activity, modifying the interaction between 
FIXa and FX, then markedly enhancing the catalytic rate constant of FIXa against FX. 
Patients with severe hemophilia A (<1% of normal FVIII level) typically suffer from 
recurrent bleeding episodes several times a month, primarily in the musculoskeletal system. 
Approximately 85% of the bleeding episodes are into joints, and repeated joint bleeding from 
early childhood results in a chronic degenerative arthritis and markedly reduces the patients’ 
quality of life. Patients are primarily treated with FVIII agents (recombinant or plasma-derived). 
However, since FVIII agents are exogenous for severely affected patients, approximately 30% 
of them develop alloantibodies against FVIII (FVIII inhibitors). FVIII inhibitors largely restrict 
treatment with FVIII agents, and consequently make it difficult to control bleeding. Furthermore, 
in severe hemophilia A patients without FVIII inhibitors, routine prophylaxis with exogenous 
FVIII to maintain FVIII levels above 1% is beneficial to prevent bleeding; however, the need 
for frequent intravenous (IV) injections with FVIII agents also negatively affects patients’ 
quality of life. 
In order to overcome these shortcomings, we created a humanized anti-factor IXa/factor X 
(anti-FIXa/FX) bispecific IgG antibody, termed ACE910, which is expected to mimic the FVIII 
cofactor function as a kind of scaffold by binding and placing FIXa and FX into spatially 
appropriate positions [38]. In this study, I evaluated (i) in vitro FVIII-mimetic activities of 
ACE910 in plasma coagulation assays, (ii) in vivo hemostatic potency of ACE910 episodic 
treatment in a newly-established short-term non-human primate model of hemophilia A, (iii) 
pharmacokinetic (PK) properties of ACE910 in non-human primates for estimating the 
possibility of routine prophylactic use, and (iv) in vivo preventive effects of ACE910 
prophylactic treatment on spontaneous bleeding including joint bleeds in a newly-established 
long-term non-human primate model of hemophilia A. By examining the in vitro FVIII-mimetic 
activities and in vivo hemostatic effects on bleeding in the hemophilia A models, I aimed at 
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elucidating the biological functions of ACE910 as a FVIII-cofactor mimetic which has a 
completely different protein structure from native FVIII. 
 
Methods and Results 
Chapter 1: In vitro FVIII-mimetic activity of ACE910 in plasma coagulation assays 
Using an enzymatic assay with purified FIXa and FX, FVIII-mimetic activities had been 
evaluated in the previous study [40]. ACE910 greatly enhanced FX activation by FIXa, whereas 
could not promote FX activation without FIXa, indicating ACE910’s binding to both FIXa and 
FX is necessary for its activity. These results also indicated ACE910 itself does not show a 
direct enzymatic action and therefore functions as a cofactor like FVIII. I next evaluated the 
activity of ACE910 in human FVIII-deficient plasma and cynomolgus monkey FVIII-inhibited 
plasma by using the unique anti-primate FVIII neutralizing antibody (termed VIII-2236). With 
respect to thrombin generation (TG) potency, ACE910 dose-dependently improved TG 
parameters in these plasma both in the presence and absence of FVIII inhibitors, whereas the 
effects of recombinant human FVIII (rhFVIII) on TG were blocked by the presence of FVIII 
inhibitors. These results indicate that ACE910 could enhance plasma coagulation even in 
patients with FVIII inhibitors who are nonresponsive to FVIII treatment. 
Chapter 2: In vivo hemostatic potency of ACE910 episodic treatment in a short-term 
non-human primate model of hemophilia A 
A short-term cynomolgus monkey model of acquired hemophilia A was established by 
injecting anti-primate FVIII neutralizing antibody (VIII-2236). When bleeds emerged following 
artificial bleed-inducing procedures in muscles and subcutis, either ACE910 or recombinant 
porcine FVIII (rpoFVIII) was intravenously administered. rpoFVIII was additionally 
administered twice daily on the following 2 days. Bleeding symptoms were monitored for 3 
days. A single bolus of 1 or 3 mg/kg of ACE910 showed hemostatic potency comparable to 10 
U/kg (twice daily) of rpoFVIII against on-going bleeds. 
Chapter 3: Pharmacokinetic properties of ACE910 in non-human primates for 
estimating the possibility of routine prophylactic use 
A PK study and multiple dosing simulations of ACE910 were performed in cynomolgus 
monkeys. The determined ACE910 PK parameters included a long half-life (3 weeks) and high 
subcutaneous (SC) bioavailability (nearly 100%). The simulation results based on PK 
parameters indicated that the hemostatic level could be maintained with once-weekly SC 
administration of ACE910, suggesting the possibility of more effective prophylaxis. 
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Chapter 4: In vivo preventive effects of ACE910 prophylactic treatment on 
spontaneous bleeding including joint bleeds in a long-term non-human primate model of 
hemophilia A 
In the Chapter 2 and 3 studies, I demonstrated in cynomolgus monkeys that a single IV 
dose of ACE910 exerted hemostatic activity against hemophilic bleeds artificially induced in 
muscles and subcutis, and that a SC dose of ACE910 showed a 3-week half-life and nearly 
100% bioavailability, offering support for effective prophylaxis for hemophilia A by 
user-friendly SC dosing. However, there was no direct evidence that such SC dosing of ACE910 
would prevent spontaneous bleeds occurring in daily life. In the Chapter 4 study, I newly 
established a long-term cynomolgus monkey model of hemophilia A by multiple IV injections 
of an anti-primate FVIII neutralizing antibody (termed cyVIII-2236) engineered in mouse–
monkey chimeric form to reduce its antigenicity. The monkeys in the control group exhibited 
various spontaneous bleeding symptoms as well as continuous the activated partial 
thromboplastin time (APTT) prolongation; notably, all exhibited joint bleeds, which are a 
hallmark of hemophilia. Weekly SC doses of ACE910 (initial 3.97 mg/kg followed by 1 mg/kg) 
significantly prevented these bleeding symptoms; notably, no joint bleeding symptoms were 
observed. ACE910 is expected to prevent spontaneous bleeds and joint damage in hemophilia A 
patients even with weekly SC dosing, although appropriate clinical investigation is required. 
 
Conclusions  
We had generated a novel humanized anti-FIXa/FX bispecific IgG antibody, ACE910. By 
examining the in vitro FVIII-mimetic activities and in vivo hemostatic effects on bleeding in the 
hemophilia A models, I elucidated the biological functions of ACE910 as a FVIII-cofactor 
mimetic which has a completely different protein structure from native FVIII. In the general 
conclusions, (i) ACE910 improved coagulation in FVIII-deficient plasma both with and without 
FVIII inhibitors, (ii) a short-term hemophilia A model expressing stable artificial bleeds with 
proper severity was newly established in cynomolgus monkeys, and single episodic IV dose of 
ACE910 significantly inhibited these bleeding symptoms, (iii) ACE910 showed the 3-week 
plasma half-life and high SC bioavailability in cynomolgus monkeys, and possibility of 
effective prophylaxis by the once-weekly SC doses was simulated based on the PK parameters, 
and (iv) a long-term acquired hemophilia A model expressing reproducible spontaneous joint 
bleeds and other bleeds was newly established in cynomolgus monkeys, and weekly SC doses 
of ACE910 significantly prevented these bleeding symptoms. These results elucidated 
 4 
 
biological functions of ACE910 as a FVIII-cofactor mimetic and suggested that ACE910 has the 
potential not only to ameliorate on-going bleeds, but also to offer a user-friendly and aggressive 
routine prophylaxis for hemophilia A patients both with and without FVIII inhibitors. Clinical 
investigation of ACE910 is currently on-going, based on the results in these studies. 
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Abbreviations 
 
Abbreviation Name 
Abs absorbance 
APTT activated partial thromboplastin time 
BiAb bispecific antibody 
CHO Chinese hamster ovary 
ELISA enzyme-linked immunosorbent assay 
FIX factor IX 
FIXa activated factor IX 
FVIII factor VIII 
FX factor X 
FXa activated factor X 
FXIa activated factor XI 
HEK293 human embryonic kidney 293 
Hgb hemoglobin 
hFIX human factor IX 
hFIXa human activated factor IX 
hFX human factor X 
hFXa human activated factor X 
IgG immunoglobulin G 
IV intravenous 
PK pharmacokinetic 
PL phospholipid 
rhFVIII recombinant human factor VIII 
rpoFVIII recombinant porcine factor VIII 
SD standard deviation 
SE standard error 
SC subcutaneous 
TF tissue factor 
TG thrombin generation 
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General Introduction 
 
Hemophilia A is a bleeding disorder caused by an inherited deficiency of blood coagulation 
factor VIII (FVIII). FVIII functions as a cofactor to promote blood coagulation when activated 
by either thrombin or activated factor X (FXa). The resultant activated factor VIII (FVIIIa) 
binds to both factor IX (FIX) and factor X (FX) which have serine protease activity when 
activated. FX is a substrate for activated factor IX (FIXa) protease. The binding properties of 
FVIII to FIXa and FX contribute to FVIII’s cofactor activity, modifying the interaction between 
FIXa and FX, then markedly enhancing the catalytic rate constant of FIXa against FX [22]. 
The severity of hemophilia A is known to correlate with the plasma FVIII level: severe, 
moderate, and mild phenotypes are defined by a plasma FVIII level of < 1, 1 to 5, and > 5 to < 
40%, respectively. Patients with severe hemophilia A (<1% of normal FVIII level) typically 
suffer from recurrent bleeding episodes several times a month, primarily in the musculoskeletal 
system, whereas moderate cases typically experience far fewer bleeding episodes and mild cases 
rarely bleed spontaneously [3, 8]. Approximately 85% of the bleeding episodes are into joints, 
and repeated joint bleeding from early childhood results in a chronic degenerative arthritis and 
markedly reduces the patients’ quality of life. 
Patients are primarily treated with FVIII agents (recombinant or plasma-derived). However, 
since FVIII agents are exogenous for severely affected patients, approximately 30% of them 
develop alloantibodies against FVIII (FVIII inhibitors) [1, 3]. FVIII inhibitors largely restrict 
treatment with FVIII agents, and consequently make it difficult to control bleeding because 
alternative bypassing agents have shorter in vivo half-lives (e.g. half a day in FVIII agent, 23 
hours in a recombinant activated factor VII agent) and are not always effective [1, 19]. Attempts 
to eradicate FVIII inhibitors with high doses of FVIII are tried, but these are very expensive and 
do not always work [14]. In severe hemophilia A patients without FVIII inhibitors, while 
traditional episodic treatment by a FVIII agent cannot prevent hemophilic arthropathy, routine 
prophylaxis with exogenous FVIII to maintain FVIII levels above 1% is beneficial to prevent 
bleeding [25, 30]; however, the need for frequent IV injections with FVIII agents also 
negatively affects patients’ quality of life and their adherence to the routine prophylactic 
regimen, typically IV injections 3 times per week, which is particularly problematic when 
treating pediatric patients at home [35]. 
Therefore, a novel drug is needed: one that is long-lasting, subcutaneously injectable, 
effective regardless of FVIII inhibitors, and does not induce FVIII inhibitors [21, 23, 33, 43]. In 
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order to overcome these shortcomings, we created a humanized anti-factor IXa/factor X 
(anti-FIXa/FX) bispecific IgG antibody, termed ACE910, which is expected to mimic the FVIII 
cofactor function as a kind of scaffold by binding and placing FIXa and FX into spatially 
appropriate positions [22, 38]. One mechanism of the cofactor action of FVIII is to maintain 
FIXa and FX in the appropriate positional relationship in the enzyme reaction on activated 
phospholipid membranes (e.g. activated platelet membrane at hemostatic site in blood) in which 
FIXa activates FX. Based on this scientific assumption, the concept of “an antibody that is a 
functional mimetic for FVIII cofactor” was devised, by which the cofactor function of FVIII is 
substituted via “a bispecific antibody that binds to FIXa with one arm and binds to FX with the 
other arm” (Figure 1). 
Given its characteristics as an IgG molecule, the bispecific antibody, finally identified 
ACE910, is expected to have the potential to help overcome a number of challenges in the 
current standard therapy for hemophilia A, including: (a) It has a long half-life in blood and, 
therefore, a potentially low dosing frequency; (b) It can be administered by SC injection 
because general antibody drugs are absorbed by SC administration; (c) It has the potential to be 
effective in patients with FVIII inhibitors because an antibody has a completely different protein 
sequences and structure from those of FVIII, therefore its immunogenicity is totally different; 
and (d) It is not expected to induce FVIII inhibitors. A series of investigations to seek such a 
bispecific antibody, we finally identified ACE910 with the capacity to be a functional mimetic 
for FVIII and with the potential to be effective in routine supplementation for hemophilia A 
patients. 
ACE910 is a clinical investigation candidate which was highly optimized using a 
multidimensional approach to improve the FVIII-mimetic cofactor activity, PK properties, 
immunogenicity, physicochemical stability, and industrial manufacturability for clinical 
application [38]. ACE910 is a humanized monoclonal modified IgG4 antibody. By 
incorporation of a modified IgG4 constant region, the molecule has also been designed to 
reduce constant region-mediated effector activity. With respect to industrial manufacturability, 
difficulties in manufacturing the bispecific antibody were overcome by identifying a common 
light chain for the anti-FIXa and anti-FX heavy chains through framework/complementarity 
determining region shuffling, by pI engineering of the two heavy chains to facilitate ion 
exchange chromatographic purification of the bispecific antibody from the mixture of 
byproducts, and by enhancing preferential hetero-dimerization of the two heavy chains through 
charge attractive interaction in the CH3 region of each heavy chain (Figure 2). These 
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antibody-engineering technologies incorporated into ACE910 molecular design greatly 
contributed to realize large-scale manufacturing of ACE910 [17, 38]. 
Using an enzymatic assay with purified FIXa and FX, FVIII-mimetic activities of ACE910 
had been evaluated in the previous study [40]. ACE910 greatly enhanced FX activation by FIXa, 
whereas could not promote FX activation without FIXa, indicating ACE910’s binding to both 
FIXa and FX is necessary for its activity. These results also indicated ACE910 itself does not 
show a direct enzymatic action and therefore functions as a cofactor like FVIII (Figure 3). 
Moreover, it was necessary to conduct in vitro assays to fully characterize the biological 
functions of ACE910 as a FVIII-cofactor mimetic which has a completely different protein 
structure from native FVIII. In the Chapter 1 study, I evaluated in vitro FVIII-mimetic activities 
of ACE910 in plasma coagulation assays. 
It also remained unproven whether this bispecific antibody approach possessed the potency 
to ameliorate on-going bleeds, which would require higher levels of FVIII, or how much 
hemostatic potency it had in comparison with FVIII. In the Chapter 2 study, I elucidated the in 
vivo hemostatic potency of ACE910, including that against on-going bleeds compared to 
rpoFVIII, using a non-human primate model of acquired hemophilia A. Because ACE910 does 
not cross-react with mouse or rat, and cross-reacts only with primate, the cynomolgus monkey 
was selected as the animal species for evaluations in in vivo non-clinical studies. In primates, 
animal models of hemophilia had been unknown until then, I newly established a short-term (4 
days) cynomolgus monkey model of acquired hemophilia A by injecting a unique 
FVIII-neutralizing antibody, VIII-2236, and evaluated in vivo hemostatic potency of ACE910 
episodic treatment in this newly-established model. 
Furthermore, in order to evaluate the potency of ACE910 in routine supplementation, I 
performed a PK study of ACE910 in cynomolgus monkeys to determine its PK parameters and 
conducted multiple dosing simulations using these parameters in the Chapter 3 study. The 
routine supplement of exogenous FVIII is aimed at keeping the FVIII level at 1% or above to 
convert a severe disease to a moderate one [3, 25]. This strategy successfully reduces bleeding 
episodes and the risk of developing hemophilic arthropathy [25]. However, the effect is not 
necessarily perfect: a recent report suggests that the risk of joint damage remains until the 
baseline factor level is 10 to 15% or higher [9]. In the Chapter 3 study, I also discuss the 
possibility of a once-weekly SC administration of ACE910 for routine supplementation that is 
more aggressive than the current one with exogenous FVIII; in other words, a regimen that can 
convert a severe disease to a mild disease. 
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In the Chapter 2 study, by using a short-term cynomolgus monkey model of hemophilia A, 
ACE910 at a single IV dose of 1 or 3 mg/kg exerted hemostatic activity against artificial 
on-going bleeds in muscles and subcutis to the same extent as rpoFVIII at twice-daily IV doses 
of 10 U/kg. Further, in the Chapter 3 study, a multiple-dosing simulation calculated from the PK 
parameters of ACE910 in cynomolgus monkeys suggested that the plasma ACE910 
concentration capable of stopping even on-going bleeds would be maintained by once-weekly 
SC administration of 0.64 to 1.5 mg/kg ACE910. 
In the Chapter 4 study, I actually evaluated the preventive effect of once-weekly SC dosing 
of 1 mg/kg ACE910 in a long-term cynomolgus monkey model of hemophilia A. Prevention of 
joint bleeding is of major importance in the care of hemophilia A patients [36]. However, it 
remained unproven whether repeated SC dosing of ACE910 could actually prevent spontaneous 
bleeding episodes, including the joint bleeds that are a pathologic hallmark of hemophilia A. To 
address this question non-clinically, I required a newly-established primate model, because 
ACE910 is highly species-specific in its FVIII-mimetic cofactor activity and a primate model of 
hemophilia A which developed joint bleeding is unknown. Therefore, in the Chapter 4 study, I 
aimed firstly to establish a long-term hemophilia A model expressing spontaneous bleeding 
episodes, including joint bleeds, in cynomolgus monkeys, and secondly to actually evaluate the 
preventive effect of once-weekly SC dosing of ACE910 in this model for investigating the 
potential of a prophylactic treatment in hemophilia A patients. 
By examining the in vitro FVIII-mimetic activities and in vivo hemostatic effects on 
bleeding in the hemophilia A models in the Chapters 1, 2, 3, and 4 studies, I aimed at 
elucidating the biological functions of ACE910 as a FVIII-cofactor mimetic which has a 
completely different protein structure from native FVIII. 
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Chapter 1 
 
 
In vitro FVIII-mimetic activity of ACE910 in plasma 
coagulation assays 
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1-1. Materials and Methods 
 
Materials 
ACE910 was expressed in human embryonic kidney (HEK) 293 or Chinese hamster ovary 
(CHO) cells which co-transfected with the mixture of plasmids encoding the humanized 
anti-FIXa heavy chain, anti-FX heavy chain and common light chain. ACE910 was purified by 
Protein A and ion-exchange chromatographies from the culture supernatant [38]. B 
domain-deleted rpoFVIII [22] was prepared as described in the following section of 
“Preparation and analysis of recombinant porcine FVIII, rpoFVIII”. Briefly, I expressed it in 
CHO cells by stable transfection. Then, rpoFVIII was purified from the supernatant by using 
ion-exchange and gel permeation chromatographies. I confirmed its purity by SDS-PAGE under 
reducing conditions and determined its activity (% = U/dL) by an APTT-based one-stage 
coagulation assay. The preparations of ACE910 and rpoFVIII were supported mainly by T. 
Wakabayashi and the protein purification team in Chugai Pharmaceutical. Recombinant human 
FVIII (rhFVIII) was purchased from Bayer HealthCare (Leverkusen, Germany). Anti-primate 
FVIII neutralizing antibody (VIII-2236) was prepared as previously presented [22]. ACE910, 
rpoFVIII, and VIII-2236 used in the later studies (the Chapters 2, 3, and 4) were prepared in the 
similar ways as described in the Chapter 1. The other purchased reagents are described in the 
following each section.  
 
Preparation and analysis of recombinant porcine FVIII, rpoFVIII 
I expressed a B domain-deleted form of rpoFVIII in CHO cells by stable transfection as 
previously described [22]. In detail, the vector employed for the transfection was designed on 
the basis of a previously reported sequence of the F8 (Sus scrofa) gene (GenBank: NM_214167) 
and the sequence of B domain-deleted human F8 gene [15, 44]. rpoFVIII was purified from the 
supernatant of rpoFVIII-containing culture medium by using Q Sepharose Fast Flow column 
(GE Healthcare Biosciences, Wauwatosa, WI, USA) with a linear 0 to 1 M NaCl gradient and 
then gel permeation chromatography on HiLoad 26/60 Superdex200pg column (GE Healthcare 
Biosciences) equilibrated in 150 mM NaCl, 10 mM histidine-HCl, 5 mM CaCl2, 0.1% (wt/vol) 
sucrose and 0.02% (wt/vol) polysorbate 80 (Junsei Chemical, Tokyo, Japan) (pH 7.0). I 
confirmed that the purified rpoFVIII showed double bands under reducing conditions in 
SDS-PAGE on which the actual molecular weight of the heavy chain and light chain of the 
rpoFVIII was consistent with the theoretical one calculated from the amino acid sequences, 
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respectively (Figure 6). I determined the FVIII activity (U/dL) of the purified rpoFVIII in an 
APTT-based one-stage coagulation assay. Fifty µL of diluted rpoFVIII or serial dilutions of 
standard reference (normal human plasma, Siemens Healthcare, Erlangen, Germany) were 
added to 50 µL of human FVIII-deficient plasma (Siemens Healthcare), followed by addition of 
50 µL of an APTT reagent (Thrombocheck APTT-SLA, Sysmex, Kobe, Japan). Activity units 
(U) of rpoFVIII were calculated from the APTT-based coagulation times of the diluted rpoFVIII 
and the standard normal human plasma, and 1 U/dL of rpoFVIII was defined as the equivalent 1 
U/dL of human FVIII in normal human plasma. The speciﬁc activity (U/mg) was calculated by 
dividing the activity of rpoFVIII with the protein amount determined by the PACE method 
using the absorbance at 280 nm [31]. The speciﬁc activity of rpoFVIII was 3610 U/mg which 
was comparable to previous reported values of rpoFVIII [10, 32] and recombinant human FVIII 
(rhFVIII) [5]. 
 
Activated partial thromboplastin time (APTT) and thrombin generation (TG) assays 
APTT and TG assays were performed with standard equipment. In the TG assay, I 
employed two kinds of triggering solutions that respectively contained factor XIa (FXIa) and 
tissue factor (TF). The solution containing human FXIa (Enzyme Research Laboratories, 
Swansea, UK) was prepared in-house and the other containing TF, PPP-Reagent LOW 
(Thrombinoscope BV, Maastricht, Netherlands) was purchased. 
I employed commercially available human FVIII-deficient plasma (< 1 U/dL) without or 
with FVIII inhibitors (53 Bethesda units) (George King Bio-Medical, Overland Park, KS, USA) 
in both the following APTT and TG assays. I also used the pooled citrated plasma of 3 male 
cynomolgus monkeys, which contained 300 µg/mL anti-primate FVIII neutralizing antibody 
(VIII-2236). 
APTT was measured with a standard method using Thrombocheck APTT-SLA reagent by a 
semi-automated coagulation analyzer, KC4 delta (Stago, Paris, France). Data were collected in 
triplicate. 
TG was measured by calibrated automated thrombography using a 96-well plate 
fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). In the TG assay, I employed two 
kinds of TG triggering solutions. One is a solution containing 0.16 nM human factor XIa 
(Enzyme Research Laboratories, Swansea, UK) and 20 µM synthetic phospholipids (10% 
phosphatidylserine, 60% phosphatidylcholine and 30% phosphatidylethanolamine; Avanti Polar 
Lipids, Alabaster, AL, USA) which was prepared as previously described [29]. Another is the 
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purchased TF-containing reagent, PPP-Reagent LOW (Thrombinoscope BV, Maastricht, the 
Netherlands). Briefly, each well in a 96-well plate was dispensed with 80 µL of the plasma 
solution containing ACE910, rhFVIII or rpoFVIII to which was then added 20 µL of a 
triggering solution. For calibration, 20 µL of Thrombin Calibrator (Thrombinoscope BV) was 
added instead of the triggering solution. To initiate the reaction, 20 µL of FluCa reagent 
prepared from FluCa kit (Thrombinoscope BV) was dispensed by the instrument as 
programmed. I analyzed the thrombograms and peak height by the instrument’s software. Data 
were collected in triplicate. 
 
Confirmation of non-reactivity of an anti-primate FVIII neutralizing antibody, VIII-2236, 
to rpoFVIII and ACE910 
As previously described, a neutralizing antibody against human FVIII, termed VIII-2236, 
was cross-reactive to cynomolgus monkey FVIII but not to porcine FVIII [22]. To confirm 
thoroughly that VIII-2236 has no neutralizing activity against rpoFVIII or ACE910, I examined 
the influence of VIII-2236 against the APTT-shortening activity of rpoFVIII, ACE910 or 
rhFVIII (control) in human FVIII-deficient plasma. Briefly, various concentrations of rhFVIII, 
rpoFVIII, or ACE910 was added to human FVIII-deficient plasma without or with 300 g/mL 
of VIII-2236, which was incubated at 37°C for 2 hours. Then, APTT of the prepared plasma 
samples was measured. 
 
Statistical analysis 
Data are presented as mean ± standard deviation (SD). The mean and SD were calculated 
by using Microsoft Excel software (Microsoft Corporation, Redmond, WA, USA). 
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1-2. Results 
 
In vitro FVIII-mimetic activity of ACE910 in plasma coagulation assays 
First, I examined the effects of ACE910 on APTT in a plasma coagulation assay. ACE910 
shortened APTT in human FVIII-deficient plasma with a similar concentration-dependency to 
that in FVIII-neutralized cynomolgus monkey plasma (Figure 4A, 4B). ACE910 also shortened 
APTT in human FVIII-deficient plasma in the presence of FVIII inhibitors, whereas the effects 
of rhFVIII on APTT were blocked by the presence of FVIII inhibitors (Figure 4A).  
To further examine the FVIII-mimetic activity of ACE910, I next examined the effects on 
thrombin burst using one of the global assays, TG assay [39]. ACE910 improved the peak 
height of FXIa-triggered TG assay in human FVIII-deficient plasma in a similar 
concentration-dependent manner to that in FVIII-neutralized cynomolgus monkey plasma 
(Figure 4C, 4D). In comparison with rhFVIII or rpoFVIII, ACE910 had a roughly comparable 
cofactor activity of improving the peak height in each species. ACE910 also improved the peak 
height in human FVIII-deficient plasma in the presence of FVIII inhibitors, whereas the effects 
of rhFVIII on TG were not observed in the presence of FVIII inhibitors (Figure 4C).  
I employed FXIa as a trigger in the above TG assay, because I had not clearly detected 
rpoFVIII activity in the standard low TF triggering condition in FVIII-neutralized cynomolgus 
monkey plasma. Beforehand, I had confirmed in human FVIII-deficient plasma that the two 
triggering conditions showed a similar concentration-dependency in the results of peak height 
for the purpose of comparing ACE910 with rhFVIII (Figure 4C, 5). I also beforehand confirmed 
rpoFVIII that I in-house prepared had been analyzed for qualification (Figure 6). 
I had also preliminarily evaluated influence of VIII-2236 on the APTT-shortening activity 
of rpoFVIII, ACE910 or rhFVIII in human FVIII-deficient plasma. In the absence of VIII-2236, 
the addition of rpoFVIII, ACE910, and rhFVIII concentration-dependently shortened the APTT 
of human FVIII-deficient plasma. The presence of VIII-2236 (300 μg/mL) canceled the 
APTT-shortening activity of rhFVIII, but not that of rpoFVIII or ACE910 at all. These results 
indicate that the anti-primate FVIII neutralizing antibody, VIII-2236, has no neutralizing 
activity against rpoFVIII and ACE910 (Figure 7). 
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Chapter 2 
 
 
In vivo hemostatic potency of ACE910 episodic treatment in a 
short-term non-human primate model of hemophilia A   
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2-1. Materials and Methods 
 
Animals and ethics 
I used 26 male cynomolgus monkeys for the in vivo hemostatic study (2.6–4.0 kg, 3 years; 
Hamri, Ibaraki, Japan). All animal studies were approved by the Institutional Animal Care and 
Use Committee of Chugai Pharmaceutical, and were conducted in accordance with the approved 
protocols and the Guidelines for the Care and Use of Laboratory Animals at the company. 
Chugai Pharmaceutical is fully accredited by the Association for Assessment and Accreditation 
of Laboratory Animal Care (AAALAC) International. 
 
In vivo hemostatic study in an acquired hemophilia A model 
Since ACE910 is highly species-specific in its FVIII-mimetic cofactor activity, 
cynomolgus monkeys were used. On Day 0, the animals received an IV injection of VIII-2236 
(10 mg/kg). Two hours thereafter, the animals were anesthetized by isoflurane inhalation and 
bruises on the body surface that might possibly have emerged by FVIII-neutralization were 
measured. Then, the following two surgical procedures were performed: a 18G-needle was 
inserted 1 cm deep into the muscle at 22 sites (2 sites in each upper arm, 3 sites in each forearm, 
4 sites on the inside of each thigh, and 2 sites on the outside of each thigh), and SC exfoliation 
by inserting the tip of forceps beneath the abdominal skin for 3 cm at 2 sites. After 
administering buprenorphine, an analgesic drug, the animals were allowed to recover from the 
anesthesia. They received this analgesic treatment twice daily (morning and evening) from Days 
0 to 2; a total of 6 doses, and their conditions were daily observed with caution. After the 
bleeding recognition, about 6 to 8 h after injuring, the animals received IV administration of 
ACE910 (0.3, 1, or 3 mg/kg; n = 4 for each group), rpoFVIII (3.4 or 10 U/kg; n = 4 for each 
group), or no test item (control; n = 6). In the rpoFVIII group, rpoFVIII was also intravenously 
administered in the morning and evening on Days 1 and 2 (a total of 5 administrations), because 
the half-life of rpoFVIII had been beforehand confirmed to be approximately half a day in the 
pharmacodynamic study of rpoFVIII in cynomolgus monkeys, which is described in the later 
part of this section. In the morning on Days 1, 2 and 3, the animals were anesthetized to 
measure the bruised areas. After the evaluation on Day 3, the animals were euthanized 
humanely. Citrated blood was collected before and 2 h after the VIII-2236 injection, about 10 
min after the test item administration on Day 0, and before measuring the bruised area on Days 
1, 2, and 3. The change in blood hemoglobin (Hgb) level was expressed as a percentage of that 
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on Day 0 (2 h after the VIII-2236 injection). 
 
Measurement of plasma ACE910 concentration 
In the in vivo hemostatic study, the plasma ACE910 concentration was determined with a 
sandwich enzyme-linked immunosorbent assay (ELISA) to quantify human IgG. I used an 
anti-human IgG gamma-chain F(ab’)2 fragment antibody produced in goat (Sigma Aldrich, St. 
Louis, MO, USA) as the solid phase antibody for capturing ACE910 and an anti-human IgG4 
monoclonal antibody-alkaline phosphatase conjugate (Southern Biotechnology Associates, 
Birmingham, AL, USA) as the detection antibody. 
 
Pharmacodynamic study of rpoFVIII in cynomolgus monkeys and multiple dosing 
simulation 
Three male cynomolgus monkeys (2.7–2.8 kg, 3 years; Hamri) received a single IV 
administration of rpoFVIII (25 U/kg). Citrated blood sampling was performed at 0.25, 0.5, 1, 2, 
4, 7, 24, 48, 72 h and 1 month after rpoFVIII administration. The plasma samples were stored at 
–80°C until measurement of rpoFVIII activity. rpoFVIII activity in each plasma sample was 
measured by APTT assay in which endogenous cynomolgus monkey FVIII was neutralized by 
the in vitro addition of VIII-2236 (300 µg/mL). The plasma samples at 1 month after rpoFVIII 
administration, to which were added VIII-2236 (300 µg/mL) and various concentrations of 
rpoFVIII in vitro, were used for preparing the standard curve for the respective animals. Based 
on the determined rpoFVIII activity, the PK parameters were analyzed. To simulate the plasma 
rpoFVIII concentrations after multiple dosing, the data of plasma rpoFVIII activity (regarded as 
rpoFVIII concentration) were analyzed using two-compartment model with first-order 
absorption, and the resulting PK parameters were used in simulation performed with SAAM II 
version 1.2 software (SAAM Institute). The PK analysis and simulation were particularly 
supported by K. Haraya in Chugai Pharmaceutical. 
 
Statistical analysis 
In the in vivo hemostatic study, data are presented as mean ± standard error (SE). The 
parametric Dunnett’s multiple comparison test (2-tailed) (SAS Preclinical Package version 5.00; 
SAS Institute Japan, Tokyo, Japan) was used to determine P value. P < 0.05 was considered 
statistically significant. 
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2-2. Results 
 
In vivo hemostatic study in an acquired hemophilia A model 
To examine the in vivo hemostatic potency of ACE910, including that against on-going 
bleeds, I newly established the cynomolgus monkey model of acquired hemophilia A by 
modifying that we previously reported [22]. Briefly, more intense injuring procedures were 
employed and the dose timing of the test item was set to after the emergence of bleeding 
symptoms so that the hemostatic action of 10 U/kg of rpoFVIII could be properly evaluated. 
The experimental protocol is illustrated in Figure 8A. An acquired hemophilia A status was 
first established by injecting anti-primate FVIII antibody, VIII-2236, which neutralizes 
endogenous FVIII but neither exogenous rpoFVIII nor ACE910 at all (Figure 7). Then, bleeding 
was artificially induced by inserting a needle in the limb muscles and by SC exfoliation on the 
abdomen. The animals in the control group showed a progressive decrease in Hgb level (anemia 
associated with hemorrhage) and expansion of bruised areas (Figure 8B, 8C). A single IV 
administration of ACE910 at 6 to 8 h after bleeding induction, when visible bleeding symptoms 
had emerged, tended to ameliorate the decrease in Hgb level (P = 0.0643 at 3 mg/kg vs. control). 
The expansion of bruised area was significantly reduced at doses of 1 and 3 mg/kg of ACE910 
(P < 0.05 vs. control). These hemostatic effects of ACE910 at 1 and 3 mg/kg were comparable 
to the hemostatic effect of dosing twice daily with 10 U/kg of rpoFVIII. In such a regimen, 
plasma concentration of rpoFVIII would reach 25 U/dL just after the first injection and would 
range between 7.4 and 46 U/dL, according to a simulation of multiple dosing of rpoFVIII based 
on the PK parameters obtained from the single-dose injection study of rpoFVIII in cynomolgus 
monkeys (Figure 9). The mean plasma concentration of ACE910 (0.3, 1, or 3 mg/kg) was, 
respectively, 6.6, 26, or 61 µg/mL (45, 180, or 420 nM) just after administration, and 3.0, 8.4, or 
34 µg/mL (21, 58, or 230 nM) on Day 3 (Figure 8D). In the clinical setting, 20 U/dL is often 
employed as the target initial FVIII level for treatment against on-going bleeds [41]. Therefore, 
IV administration of 1 to 3 mg/kg of ACE910, or a plasma concentration of 26 to 61 µg/mL 
(180 to 420 nM), is expected to exert hemostatic activity against on-going bleeds also in the 
clinical setting. 
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Chapter 3 
 
 
Pharmacokinetic properties of ACE910 in non-human 
primates for estimating the possibility of routine prophylactic use   
 20 
 
3-1. Materials and Methods 
 
Animals and ethics 
I used 12 male cynomolgus monkeys for the PK study (2.9–5.0 kg, 4–5 years; Japan 
Laboratory Animals, Tokyo, Japan). I used 24 female mice (5 weeks; Charles River, Yokohama, 
Japan and SLC, Hamamatsu, Japan) and 24 female rats (4 weeks; Charles River) for the 
immunization to generate anti-idiotype antibodies to the variable region of ACE910. The details 
of anti-idiotype antibodies are described in the following section of “Generation and preparation 
of anti-idiotype antibodies to each variable region of ACE910” in this Chapter 3 study. 
All animal studies were approved by the Institutional Animal Care and Use Committee of 
Chugai Pharmaceutical, and were conducted in accordance with the approved protocols and the 
Guidelines for the Care and Use of Laboratory Animals at the company. Chugai Pharmaceutical 
is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) International. 
 
Pharmacokinetic study 
Animals received IV administration of ACE910 (6 mg/kg; n = 3) or SC administration of 
ACE910 (0.06, 0.6, or 6 mg/kg; n = 3 for each group) in a single dose. For animals dosed 
intravenously, blood was sampled with a heparinized syringe at 0.25, 2, 8, 24, 48, 72, and 96 h, 
as well as at 7, 14, 28, 42, 56, 70, and 84 days post-dose. For animals dosed subcutaneously, 
blood was collected in the same way without sampling at 0.25 h. The plasma concentration of 
ACE910 and anti-ACE910 alloantibodies was measured by the methods described in the 
following sections. This PK study was particularly supported by Y. Sakamoto and the PK 
analysis team in Chugai Pharmaceutical. 
 
Generation and preparation of anti-idiotype antibodies to each variable region of ACE910 
I established each hybridoma producing a mouse anti-idiotype monoclonal antibody 
against FIXa-binding arm Fab (termed anti-FIXa Fab) of ACE910 or a rat anti-idiotype 
monoclonal antibody against FX-binding arm Fab (termed anti-FX Fab) of ACE910. Briefly, 12 
mice and 12 rats were immunized with the F(ab’)2 fragment consisting of anti-FIXa Fab, and 12 
mice and 12 rats were immunized with the F(ab’)2 fragment of anti-FX Fab. The lymph node 
cells and/or spleen cells were isolated from the immunized animals, and fused with murine 
myeloma P3U1 or SP2/0 cells to establish hybridoma clones. The supernatants of the 
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hybridoma clones that should contain an antibody were applied to two kinds of ELISA to detect 
binding to anti-FIXa Fab or anti-FX Fab. Then, specific binders, a mouse antibody specific to 
anti-FIXa Fab (AQ8) and a rat antibody specific to anti-FX Fab (AJ540), were selected. The 
establishment of hybridoma clones was particularly supported by T. Suzuki and the hybridoma 
preparation team in Chugai Pharmaceutical. 
Next, the variable regions of AQ8 and AJ540 were cloned. Then, I assembled the genes of 
recombinant chimeric AQ8 (rAQ8-mIgG2b) consisting of the variable regions of AQ8 and the 
constant region of mouse IgG2b (heavy chain: EMBL accession No. J00461, light chain: EMBL 
accession No. V00807) and recombinant chimeric AJ540 (rAJ540-rbtIgG) consisting of the 
variable regions of AJ540 and the constant region of rabbit IgG (heavy chain: EMBL accession 
No. L29172, light chain: EMBL accession No. X00231), and constructed the expression vectors 
for them. The vectors were transfected into HEK293 cells to express rAQ8-IgG2b and 
rAJ540-rbtIgG. After culturing the transfectants, rAQ8-IgG2b and rAJ540-rbtIgG were purified 
with recombinant Protein A and gel permeation chromatography. Preparation of the 
anti-idiotype antibodies was particularly supported by T. Kuramochi and the antibody 
engineering team in Chugai Pharmaceutical. 
 
Measurement of plasma ACE910 concentration 
In the in vivo hemostatic study of the Chapter 2, the plasma ACE910 concentration was 
determined with a sandwich ELISA to quantify human IgG as described in the Chapter 2 
methods. I used an anti-human IgG gamma-chain F(ab’)2 fragment antibody produced in goat 
(Sigma Aldrich, St. Louis, MO, USA) as the solid phase antibody for capturing ACE910 and an 
anti-human IgG4 monoclonal antibody-alkaline phosphatase conjugate (Southern 
Biotechnology Associates, Birmingham, AL, USA) as the detection antibody. 
In the PK study of the Chapter 3, the plasma ACE910 concentration was measured with the 
bridging ELISA employing rAJ540-rbtIgG as solid phase antibody for capturing ACE910 and 
rAQ8-mIgG2b as detection antibody. Alkaline phosphatase-conjugated goat anti-mouse IgG 
(Jackson ImmunoResearch Laboratories, West Grove, PA, USA) was used as secondary 
detection antibody. 
I confirmed that both ELISA methods indicated a consistent plasma concentration of 
ACE910. The bridging ELISA using the anti-idiotype monoclonal antibodies can be used to 
measure the concentration of ACE910 specifically in human plasma. 
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Detection of anti-ACE910 alloantibodies using electrochemiluminescent bridging 
immunoassay 
Anti-ACE910 alloantibodies in cynomolgus monkey plasma were detected by an 
electrochemiluminescent bridging immunoassay. Anti-ACE910 alloantibodies in plasma 
samples or serially-diluted plasma samples were incubated with biotin-labeled ACE910 and 
ruthenium-labeled ACE910, and then the immune complexes, which form in proportion to the 
concentration of anti-ACE910 alloantibodies, were captured on a streptavidin-immobilized plate 
and detected with an electrochemiluminescence detector (Meso Scale Discovery, Rockville, MD, 
USA). A confirmation test was performed to check whether each screened anti-ACE910 
alloantibodies-positive sample had a specific response to ACE910 by ascertaining whether the 
addition of a fixed amount of ACE910 to the above test system inhibited the binding of 
anti-ACE910 alloantibodies to the two types of ACE910-labelled molecules. Detection of 
anti-ACE910 alloantibodies was particularly supported by Y. Sakamoto and the PK analysis 
team in Chugai Pharmaceutical. 
 
Statistical analysis, pharmacokinetic analysis and multiple-dosing simulation 
In the PK study, the plasma ACE910 concentration data were analyzed by 
non-compartmental analysis with Phoenix WinNonlin software version 6.2 (Pharsight, St. Louis, 
MO, USA). Multiple dosing simulations were performed with SAAM II version 1.2 software 
(SAAM Institute, Seattle, WA, USA). Data are presented as mean ± SD. The PK analysis and 
simulation were particularly supported by K. Haraya in Chugai Pharmaceutical. 
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3-2. Results 
 
Pharmacokinetic study and multiple dosing simulation 
In order to evaluate the potency of ACE910 for routine supplementation, I performed a 
single-dose PK study of ACE910 to determine the PK parameters for simulating plasma 
ACE910 concentration after multiple dosing. 
The plasma half-life of ACE910 was 19.4 days after a single IV administration at 6 mg/kg, 
and in the range of 23.6 to 26.5 days after a single SC administration at 0.06, 0.6, or 6 mg/kg 
(Table 1). As for the SC administration, the maximum plasma concentration (Cmax) of ACE910 
increased in approximate proportion to the dose increment. The SC bioavailability was 102.3% 
at the 6 mg/kg dose. These results were consistent with those of our previous study [38]. For 
these analyses, I excluded two animals in which anti-ACE910 alloantibodies were detected 
respectively from 28 days after the IV administration of 6 mg/kg and from 56 days after the SC 
administration of 0.06 mg/kg. Their plasma ACE910 concentration decreased in association 
with detection of anti-ACE910 alloantibodies. 
In the in vivo hemostatic study, the mean initial plasma concentrations of ACE910 were 26 
and 61 µg/mL (180 and 420 nM) in the 1 mg/kg and 3 mg/kg groups, respectively. The 
hemostatic effect in these groups was comparable to that in the rpoFVIII 10 U/kg group, in 
which the FVIII level would lie within the range of a mild phenotype (Figure 9). I considered 
that if, by routine supplementation, a plasma ACE910 level of 26 µg/mL or above were 
maintained at all times in patients, a severe phenotype would be possibly converted to a mild 
phenotype beyond a moderate phenotype. To examine this possibility, multiple dosing 
simulations of ACE910 were performed using the parameters obtained from the PK study. The 
result of the simulations indicated that, if the target trough plasma level of ACE910 were set to 
26 µg/mL or 61 µg/mL, it could be maintained by once-weekly SC administrations of 0.64 
mg/kg or 1.5 mg/kg at a steady state, respectively (Figure 10).  
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Chapter 4 
 
 
In vivo preventive effects of ACE910 prophylactic treatment 
on spontaneous bleeding including joint bleeds in a long-term 
non-human primate model of hemophilia A   
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4-1. Materials and Methods 
 
Anti-primate FVIII neutralizing antibodies 
A mouse monoclonal anti-primate FVIII neutralizing antibody, termed VIII-2236, was 
prepared from hybridoma culture supernatants as previously presented [22, 27]. A chimeric 
mouse–monkey anti-primate FVIII neutralizing antibody, termed cyVIII-2236, was constructed 
comprising the mouse variable region from VIII-2236 and the monkey constant region of IgG, 
which I originally cloned from cynomolgus monkey thymus. The cyVIII-2236 antibody was 
produced in HEK293 cells and isolated by protein A and gel permeation chromatography from 
the culture supernatants. Preparation of cyVIII-2236 was particularly supported by T. 
Kuramochi and A. Sakamoto in Chugai Pharmaceutical. 
 
Comparison of cyVIII-2236 with VIII-2236 in APTT assay 
Firstly, to compare the FVIII-neutralizing activity between cyVIII-2236 and VIII-2236, 
each was added to citrated plasma pooled from 3 normal male cynomolgus monkeys. Then, 
APTT was measured with a standard method using Thrombocheck APTT-SLA (Sysmex) and 
coagulation analyzer KC4 Delta (Stago). Secondly, to compare the effect of cyVIII-2236 and 
VIII-2236 on the APTT-shortening activity of ACE910, each was added to FVIII-deficient 
human plasma (George King) at the final plasma concentration of 300 µg/mL together with 
various concentrations of ACE910, then APTT was measured. 
 
Animals and ethics 
Ten male cynomolgus monkeys (2.35–4.25 kg, aged 3–4 years) were purchased from 
Hamri. All animal studies were approved by the Institutional Animal Care and Use Committee 
of Chugai Pharmaceutical, and were conducted in accordance with the approved protocols and 
the Guidelines for the Care and Use of Laboratory Animals at the company. Chugai 
Pharmaceutical is fully accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) International. 
 
Long-term primate model of acquired hemophilia A 
In the first part of this Chapter 4 study, 2 cynomolgus monkeys received weekly IV 
injections (3 or 10 mg/kg each) of VIII-2236. Citrated blood was collected over time. Blood 
Hgb concentration was measured by hematology analyzer SF-3000 (Sysmex) to monitor 
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hemorrhagic anemia. APTT was assessed with a standard method using Data-Fi APTT 
(Siemens) and coagulation analyzer AMAX CS-190 (Trinity). In addition, bleeding symptoms 
(bruises [dark-red areas on the body surface], hematuria, limping, and general condition 
including joint swelling) were monitored on 21 working days from Day 0 until Day 28. To 
observe bruises easily, the body hair was sheared on Day 0, and the area of bruises and the 
number of days when bruises had been detected were assessed. 
In the second part of this Chapter 4 study, another 8 cynomolgus monkeys received weekly 
IV injections (10 mg/kg) of cyVIII-2236. Two groups (n = 4 each) were established: a control 
group (the vehicle group), treated with vehicle, and a test group (the ACE910 group), treated 
with ACE910. ACE910 was administered as an initial 3.97 mg/kg SC dose 2 h after 
cyVIII-2236 injection on Day 0, and thereafter as weekly 1 mg/kg SC doses. The same dosing 
regimen of vehicle (histidine buffer containing a surfactant) was applied to the vehicle group. 
Citrated blood was collected over time. Blood Hgb concentration was measured; the change in 
blood Hgb level was expressed as a percentage of that on Day 0 (2 h after cyVIII-2236 
injection). APTT was measured with Thrombocheck APTT-SLA and KC4 Delta. Bleeding 
symptoms were monitored on 41 working days until Day 56. Necropsy was performed on Day 
56; organs and tissues from the whole body were macroscopically examined, and hemorrhagic 
findings in joints (shoulder, elbow, wrist, hip, knee, and ankle on both sides) were scored. Then, 
they were histopathologically examined. The histopathological evaluation was particularly 
supported by K. Adachi in Chugai Pharmaceutical. 
I assessed cyVIII-2236 concentration, FVIII-neutralizing titer of cyVIII-2236, ACE910 
concentration, and development of anti-ACE910 alloantibodies. Briefly, cyVIII-2236 
concentration was determined with a sandwich ELISA using recombinant human FVIII and an 
anti-human IgG antibody. FVIII-neutralizing titers of cyVIII-2236 on Days 0 (just after 
cyVIII-2236 injection) and 56 were assessed with a modified Bethesda assay [28]. ACE910 
concentration was determined with a sandwich ELISA to quantify human IgG [27]. 
Anti-ACE910 alloantibodies present at necropsy were examined with an 
electrochemiluminescent bridging immunoassay using labeled ACE910 [27]. Detection of 
anti-ACE910 alloantibodies was particularly supported by Y. Sakamoto and the PK analysis 
team in Chugai Pharmaceutical. 
In both parts, the monkeys were carefully monitored under the supervision of the attending 
veterinarian to determine the necessity of pain relief or other treatment. Consequently, no 
monkeys received an analgesic drug. 
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Plasma cyVIII-2236 concentration 
In the in vivo efficacy study, the plasma cyVIII-2236 concentration was determined with a 
sandwich ELISA using recombinant human FVIII (rhFVIII) (Bayer HealthCare) as the solid 
phase and a goat anti-human IgG1 (gamma-chain specific) antibody biotin conjugate (Southern 
Biotechnology Associates) and Streptavidin-PolyHRP80 (Stereospecific Detection 
Technologies) as the detection system. 
 
Determination of the in vitro correlation between plasma cyVIII-2236 concentration and 
one-stage clotting assay-based FVIII:C 
In an in vitro APTT-based one-stage clotting assay, FVIII activity (FVIII:C) in the presence 
of cyVIII-2236 was assessed. Samples of cyVIII-2236 at various concentrations were mixed 
with citrated plasma pooled from 3 normal male cynomolgus monkeys. After the mixture was 
incubated at 37°C for 2 h, 50 µL of the cyVIII-2236-containg plasma diluted tenfold with 
imidazole dilution buffer (or the original pooled plasma serially diluted as standard) was added 
to 50 µL of human FVIII-deficient plasma (George King), followed by addition of 50 µL of an 
APTT reagent (Thrombocheck APTT-SLA, Sysmex). The FVIII:C was determined on the basis 
of the standard curve. 
 
FVIII-neutralizing titer of cyVIII-2236 
In the in vivo efficacy study, the FVIII-neutralizing titers of cyVIII-2236 on Day 0 (just 
after cyVIII-2236 injection) and Day 56 were assessed with a modified Bethesda assay. The 
diluted plasma sample or imidazole dilution buffer (as a control sample) was mixed with an 
equal amount of normal human plasma (Siemens) to which an anti-ACE910 FIXa-arm Fab 
antibody (termed AQ8) and an anti-ACE910 FX-arm Fab antibody (termed AJ540) were added 
(each at 300 µg/mL concentration) to completely inhibit any ACE910 activity in the sample. 
After the mixture was incubated at 37°C for 2 h, 50 µL of the plasma samples diluted 
appropriately (or serial dilutions of normal human plasma as standard) was added to 50 µL of 
human FVIII-deficient plasma (Sysmex), followed by addition of 50 µL of an APTT reagent 
(Thrombocheck APTT-SLA, Sysmex). The FVIII:C of each sample was determined, and 
Bethesda unit (BU) was calculated [28]. 
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Plasma ACE910 concentration 
In the in vivo efficacy study, the plasma ACE910 concentration was determined with a 
sandwich ELISA to quantify human IgG using a goat anti-human IgG gamma-chain F(ab’)2 
fragment antibody (Sigma Aldrich) and an anti-human IgG4 monoclonal antibody–alkaline 
phosphatase conjugate (Southern Biotechnology Associates) [27]. 
 
Anti-ACE910 alloantibodies in plasma 
In the in vivo efficacy study, anti-ACE910 alloantibodies in plasma collected at necropsy 
were examined by an electrochemiluminescent bridging immunoassay [27]. Plasma was 
incubated with biotin-labeled ACE910 and ruthenium-labeled ACE910, then the immune 
complexes, which form in proportion to the concentration of anti-ACE910 alloantibodies, were 
captured on a streptavidin-immobilized plate and detected with an electrochemiluminescence 
detector (Meso Scale Discovery). Detection of anti-ACE910 alloantibodies was particularly 
supported by Y. Sakamoto and the PK analysis team in Chugai Pharmaceutical. 
 
Simulation of plasma rpoFVIII concentration 
Based on the PK parameters of rpoFVIII obtained from the previous cynomolgus monkey 
PK study [27], the plasma rpoFVIII concentration in the in vivo efficacy study with a 
twice-weekly 20 U/kg IV dosing regimen was simulated using SAAM II version 1.2 software 
(SAAM Institute). It has been confirmed that the half-life of rpoFVIII in cynomolgus monkeys 
is about 14 h, which is almost the same as the half-life of rhFVIII in humans, and that rpoFVIII 
activity in cynomolgus monkeys and rhFVIII activity in humans are nearly identical at the same 
dosage [27]. The PK analysis and simulation were particularly supported by K. Haraya in 
Chugai Pharmaceutical. 
 
Effects of rpoFVIII on spontaneous bleeds in a long-term primate model of acquired 
hemophilia A 
In an attempt to further validate the long-term hemophilia A model by looking at reactivity 
to a FVIII agent, the effects of rpoFVIII were examined. 
The B-domain–deleted form of rpoFVIII was expressed in CHO cells by stable transfection 
[22, 27]. The transfection vector was designed on the basis of a reported sequence of the porcine 
F8 (Sus scrofa) gene (GenBank: NM_214167) and the B-domain–deleted human F8 gene [15, 
44]. rpoFVIII was purified by ion-exchange and gel permeation chromatography from the 
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culture supernatants. Activity units (U) of purified rpoFVIII were determined in an APTT-based 
one-stage clotting assay, and 1 U/dL rpoFVIII was defined as the equivalent of 1 U/dL human 
FVIII in normal human plasma (Siemens). The specific activity of rpoFVIII was 3610 U/g 
which was comparable to previous reported values of rpoFVIII and rhFVIII [5, 10, 32]. It was 
confirmed that the anti-primate FVIII neutralizing antibody cyVIII-2236 has neutralizing 
activity against rhFVIII (Figure 12B), but not against rpoFVIII. 
Four male cynomolgus monkeys (2.50–3.15 kg, aged 3–4 years) were purchased from 
Hamri. As a supplement to the second part of the study, these 4 animals received a weekly IV 
injection (10 mg/kg) of cyVIII-2236 on Days 0, 7, 14, 21, 28, 35, 42, and 49. rpoFVIII was 
administered at a 20 U/kg IV dose 2 h after cyVIII-2236 injection on Day 0 and subsequently 
twice-weekly on Days 4, 7, 11, 14, 18, 21, 25, 28, 32, 35, 39, 42, 46, 49, and 53. This dosing 
regimen was selected to maintain ≥1% rpoFVIII:C for 6 days a week. For an 8-week 
observation period, citrated blood was collected on Days 0, 4, 7, 11, 14, 18, 21, 25, 28, 32, 35, 
39, 42, 46, 49, 53, and 56 (before and 2 h after cyVIII-2236 injection on Day 0; immediately 
after rpoFVIII injection on Days 4, 11, 18, 25, 32, 39, 46, and 53; just before cyVIII-2236 and 
rpoFVIII injections on Days 7, 14, 21, 28, 35, 42, and 49). Blood Hgb concentration was 
measured; the change in blood Hgb level was expressed as a percentage of that on Day 0 (2 h 
after cyVIII-2236 injection). APTT was measured in plasma from the blood collected. In 
addition, limping was monitored on 41 working days until Day 56. Necropsy was performed on 
Day 56; hemorrhagic findings in joints (shoulder, elbow, wrist, hip, knee, and ankle on both 
sides) were scored. 
 
Statistical analysis and multiple-dosing simulation 
In the in vivo efficacy study, some were analyzed by 2-tailed Student’s t test (SAS 
Preclinical Package, version 5.00) between the vehicle and the ACE910 groups. A P value of 
0.05 or less was considered statistically significant. Multiple doses of ACE910 were simulated 
with SAAM II version 1.2 software (SAAM Institute) on the basis of the PK parameters 
determined in the Chapter 3 study. The data are presented as individual values or as mean ± SD. 
The PK analysis and simulation were particularly supported by K. Haraya in Chugai 
Pharmaceutical. 
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4-2. Results 
 
Failure of long-term neutralization of endogenous FVIII by VIII-2236 in cynomolgus 
monkeys 
First, I attempted to establish a long-term acquired hemophilia A model by weekly IV 
injection of VIII-2236 in cynomolgus monkeys. APTT prolongation was observed for the first 2 
weeks (Figure 11), but gradually shortened after the third injection, and finally disappeared by 
the end of the fourth week, suggesting the development of alloantibodies to VIII-2236. 
VIII-2236 is a mouse IgG, and therefore entirely foreign to primates. In addition, no sign of 
joint bleeds was observed, although some bruises and a transient decrease in blood Hgb were 
detected. Consequently, I sought an alternative way of establishing a longer-term primate model 
of acquired hemophilia A. 
 
Chimerization of VIII-2236 to cyVIII-2236 
As an attempt to avoid anti-VIII-2236 alloantibody development, I chimerized VIII-2236 
(mouse IgG) by replacing its constant region with that of cynomolgus monkey IgG. The 
chimerized VIII-2236 (cyVIII-2236) successfully prolonged APTT in cynomolgus monkey 
plasma in vitro with a similar concentration dependency to that of original VIII-2236 (Figure 
12A). Additionally, cyVIII-2236 did not interfere with the APTT-shortening activity of ACE910, 
the same results were also found with VIII-2236 (Figure 12B). These results indicate that 
VIII-2236 was successfully chimerized to cyVIII-2236 while retaining the original 
characteristics. 
 
Establishment of a long-term acquired hemophilia A model expressing spontaneous joint 
bleeds in cynomolgus monkeys 
Using cyVIII-2236, I retried to establish long-term neutralization of endogenous FVIII, 
expecting reproducible development of spontaneous joint bleeds. The experimental protocol is 
illustrated in Figure 13A. In all the monkeys given vehicle (n = 4), APTT was prolonged to 
approximately twice the normal baseline for 8 weeks (Figure 13B). Plasma cyVIII-2236 
concentration fluctuated, but remained over 58.6 µg/mL (nearly 400 nM) (Figure 14). As over 
400 nM cyVIII-2236 prolonged APTT by 2-fold in vitro (Figure 12A), these observation 
seemed consistent. Thus, an acquired hemophilia A state was successfully maintained by using 
cyVIII-2236. 
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In this long-lasting acquired hemophilia A state, all the control monkeys given vehicle 
developed abnormal leg motion known as limping: a behavior to avoid using the affected leg 
(Figure 13C). The limping continued until the experiments ended, with days when limping was 
detected reaching 25.0 ± 8.3 days (61% ± 20%) of the 41 observation days. Two control 
monkeys (#3 and #4) developed joint swelling at the ankle in the limping limb from Days 28 to 
42 and from Days 18 to 42, respectively. Macroscopic observation at necropsy on Day 56 
revealed intra-articular dark red areas (consistent with hemorrhagic findings in the 
histopathological examination) in joints (elbow, hip, or ankle) of all the control monkeys; the 
number of bleeding joints was 2.0 ± 0.8 per head (Figure 13D and Table 2). Bleeding was 
detected in the hip or ankle joint of the side that limped. Representative macroscopic findings of 
the hip joints are shown in Figures 13E (i) and (ii). Hemorrhagic findings or reactive findings 
associated with hemorrhage were histopathologically confirmed in the joints that limped: 
hemorrhage/hemosiderin deposition, mononuclear cell infiltration, and vascular proliferation in 
the synovial membranes; synovial hyperplasia; granulation tissue; and destruction of articular 
cartilage or underlying bone (Figure 15A, B, and C). Thus, a long-term acquired hemophilia A 
model expressing spontaneous joint bleeds was successfully established in cynomolgus 
monkeys. 
Other spontaneous bleeding symptoms, i.e. bruises and hematuria, were detected by daily 
observation in the vehicle group. By macroscopic observation at necropsy, hemorrhagic findings 
were also observed in joint, skeletal muscle (lower abdomen and femoral region), urinary 
bladder, seminal vesicle, rectum, and subcutis (back) in 1, 2, or 4 of the 4 vehicle-control 
monkeys (Table 2). Additionally, blood Hgb temporarily decreased during the observation 
period with the lowest values reaching 64% to 87% (Figure 16), suggesting substantial 
hemorrhagic blood loss. 
 
Bleeding preventive effect of ACE910 in the long-term acquired hemophilia A model 
The preventive effect of a weekly SC dose of ACE910 on spontaneous joint bleeds was 
evaluated in the model established above. The dosing regimen was simulated to maintain the 
plasma concentration trough at >30 µg/mL from the first week after administration using the PK 
parameters of ACE910 in cynomolgus monkeys previously obtained, because around 26 µg/mL 
of plasma ACE910 would show hemostatic potency comparable to that of 10 U/kg (twice-daily) 
rpoFVIII in a short-term primate model of acquired hemophilia A [27].  
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In all the monkeys treated with ACE910 (n = 4), APTT was initially prolonged to 
approximately twice the normal baseline after the first IV injection of cyVIII-2236, as in the 
group treated with vehicle. Then, repeated ACE910 administration shortened the prolonged 
APTT to the baseline level over the entire dosing period (Figure 13B), although careful 
observation indicates that the APTT-shortening effect was slightly reversed in one monkey 
(ACE910 #4) on Days 25 and 28. It should be noted that the APTT of FVIII-neutralized 
cynomolgus monkey plasma was normalized even at around 30 µg/mL (nearly 200 nM) of 
ACE910, which also indicated rpoFVIII relative activity of <10% on the basis of peak height in 
the TG assay (Figure 4B). This is assumedly because ACE910 does not require activation 
process to exert its cofactor activity, whereas FVIII needs additional time to be activated by 
thrombin or FXa in the APTT assay. Therefore, the effect of ACE910 on APTT should be 
carefully interpreted in relation to the hemostatic efficacy. Plasma cyVIII-2236 in the ACE910 
group remained over 96.1 µg/mL, which exceeded the minimal cyVIII-2236 level (58.6 µg/mL) 
in the vehicle group (Figure 14). Further, in all monkeys other than the ACE910 #4 monkey, the 
FVIII-neutralizing titer measured by the modified Bethesda assay was maintained on Day 56. 
These results suggest that endogenous FVIII was also successfully neutralized in the ACE910 
group. 
The ACE910 #4 monkey showed a rapid and significant decrease in plasma ACE910 
concentration from Day 21 to Day 28, on which it was only 2.8 µg/mL (Figure 17), and 
anti-ACE910 alloantibodies were detected in the plasma. Furthermore, this monkey accidentally 
experienced a fracture of the mandibular cuspid on Day 28, although no other monkeys 
experienced such a rare accident. Owing to the consequent massive bleeding in the oral cavity, 
the blood Hgb concentration decreased to 2.2 g/dL (19% of Day 0 values, Figure 16). Therefore, 
in consideration of animal ethics and the impossibility of maintaining an effective ACE910 level, 
this monkey was euthanized humanely on Day 28 and macroscopic observation of its organs 
and tissues was carried out at necropsy. 
In the other 3 monkeys, plasma ACE910 level remained around the target concentration 
(30 µg/mL) from Day 4 to Day 56 (Figure 17), demonstrating that the multiple-dosing 
simulation worked very well. Anti-ACE910 alloantibodies were examined in plasma collected 
at necropsy (Day 28 for the #4 monkey; Day 56 for the other 3 monkeys). In addition to the #4 
monkey, one other monkey (ACE910 #3) had anti-ACE910 alloantibodies. In this monkey, 
however, the plasma ACE910 level slightly decreased only after Day 49, and remained around 
26 µg/mL, a level which is expected to show hemostatic activity [27]. 
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Regarding the joint bleeding symptoms, no limping and no macroscopic bleeding joints at 
necropsy were observed in any of the ACE910-treated monkeys, including monkey #4. In the 
ACE910 group (n = 3; excluding #4 statistically), the number of limping days (Figure 13C) and 
the number of bleeding joints at necropsy (Figure 13D and Table 2) significantly decreased (P < 
0.01, 2-tailed Student’s t test), compared to those of the vehicle group (n = 4). In the ACE910 
group, synovial hyperplasia and vascular proliferation in the synovial membranes of joints were 
histopathologically noted (Figure 15D, E, and F). However, these findings were less severe and 
less frequent in the ACE910 group than those in the joints with neither macroscopic bleeding 
nor limping in the vehicle group. 
Regarding the other spontaneous bleeding symptoms, bruises (the maximum value of areas 
and the number of days detected during the observation period) were ameliorated, and no 
hematuria and no organ bleeds at necropsy were found except for the oral cavity bleeds of the 
ACE910 #4 monkey (Table 2). Further, monkeys #1–3 in the ACE910 group exhibited blood 
Hgb of 90% or above for 8 weeks (Figure 16). The minimum value of blood Hgb during the 
observation period was 94.9% ± 4.9% in the ACE910 group (n = 3, excluding monkey #4), 
which was significantly higher than 75.2% ± 11.3% in the vehicle group (n = 4) (P < 0.05, 
2-tailed Student’s t test). 
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General Discussion 
 
Chapter 1: In vitro FVIII-mimetic activity of ACE910 in plasma coagulation assays 
To address the remaining issues (FVIII inhibitor, frequent IV injection with FVIII and 
bypassing agents etc) in current treatment of hemophilia A, we created a humanized 
anti-FIXa/FX bispecific IgG antibody, ACE910, which is expected to mimic the FVIII cofactor 
function as a kind of scaffold by binding and placing FIXa and FX into spatially appropriate 
positions [22]. ACE910 is a clinical investigation candidate which was highly optimized using a 
multidimensional approach to improve the FVIII-mimetic cofactor activity, PK properties, 
immunogenicity, physicochemical stability, and industrial manufacturability for clinical 
application [38].  
However, it was necessary to clarify whether the biological functions of ACE910 can 
actually achieve the target profiles which are expected by its basic characteristics as a 
FVIII-function mimetic IgG molecule. Therefore, I conducted various in vitro and in vivo assays 
to fully characterize the biological functions of ACE910 which has a completely different 
protein structure from native FVIII. In the enzymatic assay with purified FIXa and FX, ACE910 
greatly enhanced FX activation by FIXa, whereas could not promote FX activation without 
FIXa, indicating ACE910’s binding to both FIXa and FX is essential for its function and 
ACE910 is a cofactor like FVIII which has no direct enzymatic activity (Figure 3).  
Furthermore, in the Chapter 1 study, I demonstrated ACE910 promotes plasma coagulation, 
e.g. shortening APTT and enhancing TG, in human FVIII-deficient plasma with a 
concentration-dependency similar to that in FVIII-neutralized cynomolgus monkey plasma 
(Figure 4). ACE910 also could promote plasma coagulation in human FVIII-deficient plasma in 
the presence of FVIII inhibitors, whereas the effects of rhFVIII on TG were not observed in the 
presence of FVIII inhibitors (Figure 4A, 4C). These results suggest that ACE910 has the 
potential to be effective in patients with FVIII inhibitors because an antibody has a completely 
different protein sequences and structure from those of FVIII, therefore its immunogenicity is 
totally different. 
In comparison with TG potential between ACE910 and rhFVIII/rpoFVIII, I hypothesized 
that around 300 nM (44 µg/mL) of plasma ACE910 would exert an in vivo hemostatic potency 
equivalent to 10 U/dL (10%) of FVIII, since 300 nM of ACE910 exhibited in vitro cofactor 
activity similar to that of 10 U/dL of FVIII in terms of the peak height in TG assays (Figure 4C, 
4D). When making this hypothesis, I did not use the APTT data. ACE910 strongly shortened 
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APTT even beyond the level achieved by 100 U/dL of FVIII at more than 300 nM (Figure 4A, 
4B), but I considered that this phenomenon should be attributed to the fact that FVIII requires 
additional time to be activated by thrombin or FXa, whereas ACE910 does not. In order to 
prove the hypothesis, I next examined the in vivo hemostatic activity of ACE910 on 
injury-induced on-going bleeds in a short-term non-human primate model of hemophilia A in 
the Chapter 2 study. 
 
Chapter 2: In vivo hemostatic potency of ACE910 episodic treatment in a short-term 
non-human primate model of hemophilia A 
In the Chapter 2 study, I elucidated the in vivo hemostatic potency of ACE910, including 
that against on-going bleeds compared to rpoFVIII, using a short-term non-human primate 
model of hemophilia A. An acquired hemophilia A status was established by injecting 
anti-primate FVIII antibody, VIII-2236, which neutralizes endogenous primate’s FVIII but 
neither exogenous rpoFVIII nor ACE910 at all (Figure 7). Therefore, rpoFVIII can work as a 
positive reference in this model.  
It had remained unproven whether the bispecific antibody approach possessed the potency 
to ameliorate on-going bleeds, which would require higher levels of FVIII, or how much 
hemostatic potency it had in comparison with FVIII. In the clinical setting, the treatment against 
on-going bleeds minimally requires 10 to 20 U/dL of the plasma FVIII level, which is much 
higher than the level required for prophylactic bleeding prevention (1 U/dL). However, the 
degree of in vivo hemostatic potency of ACE910 remained unproven.  
As a result, IV administration of 10 U/kg (twice daily) of rpoFVIII showed a significant 
hemostatic effect, whereas the hemostatic effect of 3.4 U/kg (twice daily) of rpoFVIII was not 
clearly detected in this model. The multiple dosing simulations of rpoFVIII in cynomolgus 
monkeys indicated that, by twice-daily doses of 3.4 or 10 U/kg, the plasma rpoFVIII level 
would be, respectively, 8.5 or 25 U/dL at the outset, would remain at more than 2.5 or 7.4 U/dL, 
and would reach a maximum of 16 or 46 U/dL by the end of the observation period (Figure 9). 
Therefore, I judged that this established model was well validated in terms of the reactivity to 
FVIII. Using this validated model, I elucidated the in vivo hemostatic potency of ACE910. A 
single IV administration of ACE910 at 1 or 3 mg/kg ameliorated bleeding symptoms to an 
extent equivalent to that achieved by twice-daily doses of 10 U/kg of rpoFVIII. Among the 
results, it seems contradictory that the mean bruised area of the ACE910 1 mg/kg group was 
smaller than the 3 mg/kg group. From the viewpoint of ethics for primates, I employed the 
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minimum number of animals possible to detect a hemostatic effect. Therefore, I think that this 
variance of dose dependency occurred incidentally, because the deviation in bruised area was 
rather large. 
The PK profiles of ACE910 and rpoFVIII were different, and therefore it is quite difficult 
to compare their in vivo hemostatic activity in terms of plasma level. However, to say the least, 
the hemostatic activity at the maximum plasma level of ACE910, 26 or 61 µg/mL, would have 
reached that at the minimum plasma level of rpoFVIII, 7.4 U/dL. If the two agents were 
compared by their initial plasma levels, 26 or 61 µg/mL of plasma ACE910 would have 
exhibited a hemostatic activity equivalent to that of 25 U/dL of rpoFVIII. Considering that 
ACE910 should work equivalently in human and cynomolgus monkey (Figure 4C, 4D) together 
with the fact that ACE910 fully exerted its activity even in the presence of FVIII inhibitors 
(Figure 4A, 4C), ACE910 will be possibly an effective and long-acting treatment option to 
ameliorate on-going bleeds in patients both with and without FVIII inhibitors. 
 
Chapter 3: Pharmacokinetic properties of ACE910 in non-human primates for estimating 
the possibility of routine prophylactic use 
I also consider that ACE910 will be highly valuable for routine prophylaxis against 
bleeding. Current routine prophylaxis with exogenous FVIII is aimed at converting a severe 
disease (< 1 U/dL of FVIII) to a moderate one (1–5 U/dL), but it requires frequent venous 
access, typically 3 times a week. This negatively affects both the implementation of and 
adherence to the supplementation routine, particularly for pediatric patients treated at home [1]. 
In addition, development of FVIII inhibitors deprives them of this treatment option. As ACE910 
is expected to be a long-acting, subcutaneously injectable agent that is unaffected by the 
presence of FVIII inhibitors, it will be able to resolve the drawbacks inherent to exogenous 
FVIII and its prophylactic use [21, 23, 33]. Furthermore, although routine prophylaxis with 
exogenous FVIII effectively reduces joint bleeds and prevents joint damage, its prophylactic 
effect is not always perfect [25, 30]. In line with it, the clinical outcomes of patients with 
moderate hemophilia A vary, and the proportion of them that suffers from joint impairment is 
not negligible [8]. Therefore, keeping FVIII levels within the range of a mild phenotype (> 5 
U/dL) may provide patients with substantial benefits in terms of preserving joint status and 
enabling patients to participate in physical activities [6]. As mentioned in the Chapter 2 study, 
even if conservatively estimated, 61 µg/mL of plasma ACE910 would be expected to exhibit a 
hemostatic activity within the range of a mild phenotype. 
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Generally, PK data of therapeutic antibodies from cynomolgus monkeys can be scaled to 
project human PK profiles [7], and the simulated plasma concentration-time profiles from the 
PK parameters are known to be comparable to actual observed profiles for therapeutic 
antibodies [11]. Therefore, I conducted multiple dosing simulations using the PK study data in 
cynomolgus monkeys, and found that 61 µg/mL of plasma ACE910 would be maintained at a 
steady state by once-weekly SC administration of 1.5 mg/kg (Figure 10). The simulation is, of 
course, not actual data, but I have since confirmed that the simulation of time profile of plasma 
ACE910 concentration using the above PK parameters well predicted the actual data in another 
cynomolgus monkey study employing multiple dosing of ACE910 (unpublished data). 
Therefore, I think that the simulation would work well. 
In the PK study, 2 out of 12 animals developed anti-ACE910 alloantibodies. In cynomolgus 
monkeys, development of anti-humanized antibody alloantibodies is theoretically inevitable, 
and reports of their incidence rate varies (0% to 100%) [34]. Unfortunately, it has been found 
that the immunogenicity in cynomolgus monkeys cannot predict that in human, because a 
humanized antibody is a foreign protein in cynomolgus monkeys [34]. 
In terms of SC injection, the upper limit of the dosing amount is generally considered to be 
1 mL or less than 2 mg/kg of therapeutic antibodies [18], and ACE910 has solubility sufficiently 
high to realize such a SC dosage with a small injection volume [38]. Thus, I expect that 
once-weekly SC administration of ACE910 will realize a more aggressive routine prophylaxis 
aimed at achieving a mild phenotype in hemophilia A patients both with and without FVIII 
inhibitors. 
In conclusion, the Chapter 1, 2, and 3 studies suggested that ACE910 has the potential not 
only to ameliorate on-going bleeds even in patients with FVIII inhibitors, but also to offer a 
user-friendly and aggressive routine prophylaxis for patients both with and without FVIII 
inhibitors [27]. 
 
Chapter 4: In vivo preventive effects of ACE910 prophylactic treatment on spontaneous 
bleeding including joint bleeds in a long-term non-human primate model of hemophilia A 
Joint damage is one of the most problematic bleeding-related complications in hemophilia 
A patients. Manco-Johnson et al. demonstrated in a prospective clinical study that the 
progression of joint damage could be decreased by routine alternate-day doses of FVIII from 
infancy [25]. Although this dosing regimen could render a severe disease (<1% FVIII:C) into a 
moderate one (1% – 5%), its preventive effect on joint bleeds was not perfect [6, 25] and an 
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analysis by den Uijl et al. determined that the threshold FVIII:C level required to be free from 
joint bleeds would be 12% [9]. The Chapter 2 study in a primate model of acquired hemophilia 
A predicted that ≥26 µg/mL ACE910 would exhibit hemostatic activity within the range of the 
mild phenotype (>5%) (Figure 8) and that such a hemostatic level would be maintained by 
weekly SC doses of 0.64 mg/kg ACE910 (Figure 10). Therefore, in the Chapter 4 study, I 
investigated weekly SC doses of 1 mg/kg ACE910 and actually demonstrated that such a 
regimen significantly prevented spontaneous joint bleeding, which also confirmed that the 
simulation of plasma ACE910 concentrations worked well. Because PK data of therapeutic 
antibodies from cynomolgus monkeys can be scaled to project human PK profiles [7, 34], a 
similar PK profile and efficacy are expected for ACE910 in a clinical setting. 
In the Chapter 4 study, a long-term acquired hemophilia A model was newly established. 
The FVIII:C in this model was speculated to keep <4% and <3% in the vehicle and ACE910 
groups, respectively, according to plasma cyVIII-2236 level and the cyVIII-2236 concentration 
vs FVIII:C correlation in the pooled cynomolgus monkey plasma (Figures 14, 18). 
In the case of congenital hemophilia A, a small % of FVIII:C is considered to render the 
severity of bleeding; however, in acquired hemophilia A, measured FVIII:C does not necessarily 
correlate with the severity [12]. Although cyVIII-2236 would not have necessarily decreased 
FVIII:C in the one-stage clotting assay to <1% in the monkeys, the control monkeys actually 
presented severe bleeding symptoms. Thus, I considered that this model was a severe acquired 
hemophilia A one. In an attempt to further validate this model by looking at reactivity to 
injected FVIII, I examined the effects of rpoFVIII, which is not neutralized by cyVIII-2236. 
Aiming to evaluate the marginal level of rpoFVIII efficacy, I administered rpoFVIII for 8 weeks 
with a twice-weekly 20 U/kg IV dosing regimen, which was set to keep ≥1% rpoFVIII:C for 6 
days a week (Figures 19 and 20A) [41].  
The prolonged APTT was shortened immediately after the initial rpoFVIII injection (Figure 
20B); however, in 3 of 4 monkeys, the APTT-shortening effect gradually disappeared in the 
middle of the dosing period, suggesting that anti-rpoFVIII alloantibodies had developed. In 
terms of bleeding symptoms, the number of days with limping was lower in the rpoFVIII group 
than in the vehicle group (Figure 20C); further, the course of blood Hgb tended to worsen when 
anti-rpoFVIII alloantibodies presumably emerged (Figure 20D). In the monkey in which 
rpoFVIII maintained the APTT-shortening effect, limping and decrease in blood Hgb were not 
observed; nevertheless, 2 bleeding joints were noted by macroscopic observation at necropsy. 
Although it was difficult to fully evaluate the effect of rpoFVIII because anti-rpoFVIII 
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alloantibodies developed, these results suggest that increasing FVIII activity could ameliorate 
the bleeding tendency in this model; however, the twice-weekly 20 U/kg IV dosing regimen was 
not sufficient to fully prevent joint bleeding. 
ACE910 and rpoFVIII are proteins foreign to cynomolgus monkeys; therefore, the 
development of alloantibodies to these is theoretically inevitable [11]. Incidence rates of 
anti-humanized antibody alloantibodies in cynomolgus monkeys are reported to vary (0% to 
100%), and antigenicity in cynomolgus monkeys cannot predict that in humans [34]. Although 
the antigenicity risk score of ACE910 in an in silico T-cell epitope prediction system was 
comparable to that of trastuzumab and palivizumab, which are non-immunogenic in a clinical 
setting [38], the rate of anti-ACE910 alloantibody development must be evaluated in the actual 
clinical setting. 
In this long-term acquired hemophilia A model, joint damage involving abnormal motion 
and histopathological features associated with intra-articular hemorrhage were similar to those 
of hemophilia A patients [36, 37]. While a number of animal models have been reported for 
hemophilia A, it has been difficult to develop reproducible spontaneous joint bleeds [26, 42]. 
The FVIII-deficient mouse model of hemophilia A needs an artificial injuring procedure to 
induce joint bleeding [16, 26]. Although congenital hemophilia A models in dogs, sheep, rats, 
and pigs, have been reported to develop joint bleeds, it seems difficult to express reproducible 
joint bleeds in individuals and to efficiently evaluate drug efficacy in a practicable experimental 
period [4, 16, 20, 24]. Our model stably developed leg-joint damage within 8 weeks, which was 
possibly produced by the severe acquired hemophilic state and by bodyweight loading due to 
the bipedal motion of the monkeys. Thus, this model may be particularly useful in testing the 
efficacy of therapeutic agents from the orthopedic aspect of hemophilia A. In addition, this 
primate model should be useful for the many therapeutic antibodies that have poor interspecies 
cross-reactivity. Moreover, along with our model of hemophilia A, the strategy of using a 
mouse–host animal chimeric antibody may be beneficial for establishing long-term acquired 
animal models of other protein-deficiency diseases in the hematology research field. 
Although limping and macroscopic intra-articular hemorrhage at necropsy were observed 
in all 4 control monkeys, joint swelling was noted in only 2 monkeys. Therefore, it was not so 
reproducible and may be inappropriate for quantitative assessment. The joint swelling was 
linked to limping in the both monkeys. However, in one of the monkeys (vehicle #4), the ankle 
joint that had swollen did not present macroscopic intra-articular hemorrhage. I assume that the 
intra-articular hemorrhage may have been absorbed during 2 weeks after the remission of joint 
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swelling. 
In the Chapter 4 study, although ACE910 completely prevented the macroscopic joint 
impairment, subclinical histopathological changes in the joint synovium were found, despite the 
presence of ACE910. I assume that the subclinical or small joint bleeds would occur in this 
model, and ACE910 prevented them from becoming larger and from leading to clinical 
symptoms, but did not provide a histopathological complete recovery at around 30 µg/mL of 
plasma ACE910 concentration. An appropriate clinical investigation will be required to 
elucidate whether such an action of ACE910 can completely prevent macroscopic and clinical 
joint damage in the long run. 
In conclusion of the Chapter 4 study, a long-term acquired hemophilia A model expressing 
reproducible spontaneous joint bleeds and other bleeds was newly established in cynomolgus 
monkeys, and weekly SC doses of ACE910 significantly prevented these bleeding symptoms 
[28]. The difficulty in venous access negatively affects the adoption of and adherence to the 
routine prophylaxis regimen in home settings [2]. ACE910 is expected to provide hemophilia A 
patients, regardless of FVIII inhibitors, with a more effective and user-friendly way of bleeding 
prophylaxis. 
 
General conclusion 
We had generated a novel humanized anti-FIXa/FX bispecific IgG antibody, ACE910 [38]. 
By examining the in vitro FVIII-mimetic activities and in vivo hemostatic effects on bleeding in 
the hemophilia A models, I elucidated the biological functions of ACE910 as a FVIII-cofactor 
mimetic which has a completely different protein structure from native FVIII. In the general 
conclusions (Figure 21), (i) ACE910 improved coagulation in FVIII-deficient plasma both with 
and without FVIII inhibitors, (ii) a short-term acquired hemophilia A model expressing stable 
artificial bleeds with proper severity was newly established in cynomolgus monkeys, and single 
episodic IV dose of ACE910 significantly inhibited these bleeding symptoms, (iii) ACE910 
showed the 3-week plasma half-life and high SC bioavailability in cynomolgus monkeys, and 
possibility of effective prophylaxis by the once-weekly SC doses was simulated based on the 
PK parameters, (iv) a long-term acquired hemophilia A model expressing reproducible 
spontaneous joint bleeds and other bleeds was newly established in cynomolgus monkeys, and 
weekly SC doses of ACE910 significantly prevented these bleeding symptoms. These results 
elucidated biological functions of ACE910 as a FVIII-cofactor mimetic and suggested that 
ACE910 has the potential not only to ameliorate on-going bleeds, but also to offer a 
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user-friendly and aggressive routine prophylaxis for hemophilia A patients both without and 
with FVIII inhibitors. Clinical investigation of ACE910 is currently on-going, based on the 
results in these studies. 
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Tables 
 
Table 1 (page 23). Pharmacokinetic parameters of ACE910 in cynomolgus monkeys 
 
The plasma half-life of ACE910 was 19.4 days after a single IV administration at 6 mg/kg, and in the 
range of 23.6 to 26.5 days after a single SC administration at 0.06, 0.6, or 6 mg/kg in cynomolgus 
monkeys. As for the SC administration, the maximum plasma concentration (Cmax) of ACE910 increased 
in approximate proportion to the dose increment. The SC bioavailability was 102.3% at the 6 mg/kg dose. 
  
(A) Intravenous administration        
Dose 
(mg kg
−1
) 
  
t1/2 
(day) 
AUC0-inf 
(µg·day mL
−1
) 
      
6.0 Mean
a)
 19.4 1630       
            
              
(B) Subcutaneous administration         
Dose 
(mg kg
−1
) 
  
t1/2 
(day) 
AUC0-inf 
(µg·day mL
−1
) 
tmax 
(day) 
Cmax 
(µg mL
−1
) 
Bioavailability 
(%) 
0.060 Mean
a)
 26.5 24.6 3.00 0.602 
        
0.60 Mean
b)
 24.7 189 5.00 5.10 
  SD 8.1 45 1.73 0.21 
6.0 Mean
b)
 23.6 1670 5.33 45.7 102.3 
  SD 3.2 140 2.89 5.2 
a) n = 2 , b) n = 3   
 1 
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Table 2 (page 31). Macroscopic hemorrhagic findings at necropsy on Day 56 in a long-term 
primate model of acquired hemophilia A 
 
By macroscopic observation at necropsy on Day 56 in the long-term primate model of acquired 
hemophilia A, hemorrhagic findings were observed in joint, skeletal muscle (lower abdomen and femoral 
region), urinary bladder, seminal vesicle, rectum, and subcutis (back) in 1, 2 or 4 of the 4 vehicle-control 
monkeys. No macroscopic organ bleeds at necropsy were found in any of the ACE910-treated monkeys 
(n = 3; excluding #4 monkey). 
  
Organ/tissue Site 
Number of animals with findings 
Vehicle 
(n = 4) 
ACE910 
(n = 3) 
Joint Elbow 
 
Hip 
 
Ankle 
left 
right 
left 
right 
left 
1 
1 
4 
1 
1 
0 
0 
0 
0 
0 
Skeletal muscle Lower abdomen 
Femur 
 
2 
1 
0 
0 
Urinary bladder Wall  2 0 
Seminal vesicle Serosa  1 0 
Rectum Serosa  1 0 
Skin Back subcutis 1 0 
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Figures 
 
 
Figure 1 (page 7). Schematic illustration of the FVIII-mimetic cofactor action of an 
anti-FIXa/FX bispecific antibody. (A) Activated FVIII (FVIIIa) supports the interaction between 
activated factor IX (FIXa) and factor FX (FX) through its binding to both factors on the activated 
phospholipid membrane at a coagulation site. (B) An anti-FIXa/FX bispecific antibody binds to FIXa and 
FX, promoting the interaction between FIXa and FX, enhancing the generation of activated FX (FXa), 
and exerting FVIII-mimetic cofactor activity. 
FVIIIa
Anti-FIXa/FX bispecific antibody
FIXa FX
FIXa FX
Activated phospholipid membrane
A2
A1
A3
C2C1
FXa
FXa
Activated phospholipid membrane
(A)
(B)
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Figure 2 (page 7). Antibody-engineering technologies incorporated into ACE910 molecular 
design [17]. The difficulties in manufacturing the asymmetric bispecific antibody were overcome by 
identifying a common light chain for the anti-FIXa and anti-FX heavy chains through 
framework/complementarity determining region shuffling, by pI engineering of the two heavy chains to 
facilitate ion exchange chromatographic purification of the bispecific antibody from the mixture of 
byproducts, and by enhancing preferential hetero-dimerization of the two heavy chains through charge 
attractive interaction in the CH3 region of each heavy chain. 
  
 Manufacturing an asymmetric bispecific antibody (BiAb) is challenging
 Three antibody-engineering technologies are used to manufacture BiAb
Manufacture 
unfeasible
10 H/Lch
combinations 
 B
• Common Lch by 
FR/CDR shuffling
3 H/L 
combinations 
• Isoelectric point 
(pI) engineering
: Decrease pI
: Increase pI
IEC purification 
of BiAb
+/- ++--
Charge 
difference
• Preferential Hch
heterodimerization by 
charge attractive force
Improve expression 
efficiency of BiAb
A B
+ -
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Figure 3 (page 8). ACE910 enhances FX activation by FIXa in the enzymatic assay, 
indicating FVIII-mimetic cofactor function [40]. ACE910’s action depends on the presence of 
FIXa, suggesting ACE910 is a cofactor but not an active enzyme. 
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Figure 4 (page 14). FVIII-mimetic cofactor activity of ACE910 in human FVIII-deficient 
plasma without and with FVIII inhibitors and in FVIII-neutralized cynomolgus monkey 
plasma. Effects of ACE910, rhFVIII, or rpoFVIII on APTT (A, B) and on peak height of thrombin 
generation triggering the intrinsic pathway (C, D), in human FVIII-deficient plasma without and with 
FVIII inhibitors (A, C) and in FVIII-neutralized cynomolgus monkey plasma (B, D). Data are expressed 
as mean ± SD (n = 3). In the some data plotted on the Figure 4, the bars depicting SD are shorter than the 
height of the symbols. 
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Figure 5 (page 14). Effects of ACE910 or rhFVIII on peak height of thrombin generation 
triggered by low TF in human FVIII-deficient plasma without FVIII inhibitors. Data are 
expressed as mean ± SD (n = 3). In the some data plotted on the Figure 5, the bars depicting SD are 
shorter than the height of the symbols. 
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Figure 6 (page 14). SDS-PAGE analysis of rpoFVIII. Purified rpoFVIII (0.95 μg) was analyzed 
by SDS-PAGE using 4–20% gradient gel under reducing conditions, followed by staining with coomassie 
brilliant blue. The positions of molecular mass markers in kDa are indicated to the left. SDS-PAGE 
analysis represented two bands of apparent mass approximately 90 and 80 kDa, which were consistent 
with the theoretical molecular weight of the heavy chain and light chain of rpoFVIII respectively. 
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Figure 7 (page 14). Influence of VIII-2236 on the APTT-shortening activity of rpoFVIII, 
ACE910 or rhFVIII in human FVIII-deficient plasma. In the absence of VIII-2236, the addition 
of rpoFVIII, ACE910 and rhFVIII concentration-dependently shortened the APTT of human 
FVIII-deficient plasma. The presence of VIII-2236 (300 g/mL) canceled the APTT-shortening activity of 
rhFVIII, but not that of rpoFVIII or ACE910 at all. These results indicate that the anti-primate FVIII 
neutralizing antibody, VIII-2236, has no neutralizing activity against rpoFVIII and ACE910. Data are 
expressed as mean ± SD (n = 3). The bars depicting SD are shorter than the height of the symbols. 
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Figure 8 (page 18). In vivo hemostatic activity of ACE910 against on-going bleeds in an 
acquired hemophilia A model. (A) The experimental protocol used. Time course changes of (B) 
hemoglobin level and (C) bruised areas in the control group (no test item; n = 6), the ACE910 group (0.3, 
1, or 3 mg/kg; n = 4 for each group), and the rpoFVIII group (3.4 or 10 U/kg; n = 4 for each group). 
Asterisks show statistical significance of the data on Day 3 (*P < 0.05, **P < 0.01 vs. control). (D) Time 
course of plasma ACE910 concentration in the ACE910 groups. Data are expressed as mean ± SE. 
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Figure 9 (page 18). Pharmacodynamic study and multiple dosing simulations of rpoFVIII 
in cynomolgus monkeys. (A) Time course of rpoFVIII activity in plasma after a single intravenous 
administration of 25 U/kg of rpoFVIII. Data are expressed as mean  SD (n = 3). (B) Simulated plasma 
levels of rpoFVIII are shown for the dosing regimens (twice-daily intravenous doses of 3.4 and 10 U/kg) 
adopted in the in vivo hemostatic study. The intervals between the doses were set as follows: 16 h for the 
1st2nd doses and the 3rd4th doses, and 8 h for the 2nd3rd doses and the 4th5th doses. 
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Figure 10 (page 23). Examples of simulations; plasma ACE910 concentration after 
multiple dosing in cynomolgus monkeys. The time course of plasma ACE910 concentration was 
simulated using the pharmacokinetic study data in cynomolgus monkeys for the case of once-weekly 
subcutaneous administration at 0.64 or 1.5 mg/kg starting 7 days after the initial bolus intravenous 
administration of 3.63 or 8.53 mg/kg, respectively. 
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Figure 11 (page 30). Change in APTT after weekly IV injection of the mouse anti-primate 
FVIII neutralizing antibody VIII-2236 in cynomolgus monkeys. VIII-2236 was injected at 3 or 
10 mg/kg IV doses to cynomolgus monkeys on Days 0, 7, 14, and 21. Citrated blood was collected on 
Days 0, 3, 7, 10, 14, 17, 21, 24, and 28 (before and 2 h after VIII-2236 injection on Days 0, 7, 14, and 21). 
The time course of APTT is shown for each monkey. 
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Figure 12 (page 30). Comparison of the mouse–monkey chimeric anti-primate FVIII 
neutralizing antibody cyVIII-2236 with the original mouse antibody VIII-2236 in an APTT 
assay. (A) Effects of cyVIII-2236 and VIII-2236 on APTT in normal cynomolgus monkey plasma. (B) 
Influence of 300 µg/mL cyVIII-2236 and VIII-2236 on APTT-shortening activity of ACE910 in 
FVIII-deficient human plasma. Data are expressed as means ± SD (n = 3). The bars depicting SD are 
shorter than the height of the symbols. The symbols for the group without anti-FVIII antibody are hidden 
behind the symbols for the other groups in Figure 12B. 
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Figure 13 (page 30). Preventive effects of ACE910 on spontaneous joint bleeds in a 
long-term primate model of acquired hemophilia A. (A) Experimental protocol used for 
evaluating preventive effects of ACE910 in a long-term hemophilia A model induced by the weekly IV 
doses of 10 mg/kg cyVIII-2236. The 8 cynomolgus monkeys received weekly IV injections of 
cyVIII-2236 on Days 0, 7, 14, 21, 28, 35, 42, and 49. ACE910 was administered as an initial 3.97 mg/kg 
SC dose 2 h after cyVIII-2236 injection on Day 0, and thereafter as a weekly 1 mg/kg SC dose on Days 7, 
14, 21, 28, 35, 42, and 49. Citrated blood was collected on Days 0, 4, 7, 11, 14, 18, 21, 25, 28, 32, 35, 39, 
42, 46, 49, 53, and 56 (before and 2 h after cyVIII-2236 injection on Day 0; just before cyVIII-2236, 
vehicle, and ACE910 injections on Days 7, 14, 21, 28, 35, 42, and 49). (B) The time courses of APTT are 
shown as individual values for respective cynomolgus monkeys (#1–4) of the vehicle and ACE910 
groups. The APTT of the vehicle #3 monkey on Day 46 was not determined due to a handling failure. (C) 
The days in which limping was observed are shown in red for the individual cynomolgus monkeys. The 
grey boxes indicate that no data is available because the ACE910 #4 monkey was euthanized for humane 
reasons on Day 28 (See Results). The number of days with limping (panel C) and the number of bleeding 
joints at necropsy (D) are shown as individual values (#1–4) and as means ± SD in the vehicle group (n = 
4) and the ACE910 group (n = 3). **P < 0.01 indicates significant differences from the vehicle group 
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(2-tailed Student’s t test). (E) Representative macroscopic findings of the joints at necropsy. Left hip joint 
with limping in the vehicle #1 monkey; dark-red area in the Af (i) and Hf (ii) is detected. Left hip joint 
without limping in the ACE910 #3 monkey; no abnormalities are noted in the Af (iii) and Hf (iv). The 
scale bar in each panel indicates 10 mm length. Abbreviations: Ac, acetabulum; Af, acetabular fossa; Hf, 
head of femur. 
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Figure 14 (page 30). Plasma cyVIII-2236 concentrations in a long-term primate model of 
acquired hemophilia A. The time courses of plasma cyVIII-2236 concentration in the in vivo efficacy 
study are shown. Data are expressed as individual values in cynomolgus monkeys (#1–4) of the vehicle 
and ACE910 groups. The ACE910 #4 monkey was euthanized humanely on Day 28 after anti-ACE910 
alloantibodies developed, plasma ACE910 concentration decreased, and accidental bleeding occurred. 
Thus, the measurement values for the ACE910 #4 monkey are not present after Day 28. The other missing 
values at various time points are due to handling failures of measurement or an insufficient volume of 
sample plasma. 
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Figure 15 (page 31). Histopathological findings in a representative joint in a long-term 
primate model of acquired hemophilia A. Left hip joint with limping in the vehicle #1 monkey (A, 
B, and C) and left hip joint without limping in the ACE910 #3 monkey (D, E, and F) are shown at 
original magnification ×5 (A and D), ×20 (B and E), and ×400 (C and F). Hemorrhagic changes 
(arrowheads) including hemosiderin deposition (arrows) and destruction of articular cartilage/underlying 
bone (*) are detected in the joint with limping (A, B, and C). No hemorrhagic changes are noted in the 
joint without limping (D, E, and F). Abbreviations: Aca, articular cartilage of acetabulum; Hb, hip bone; 
Sm, synovial membrane. Hematoxylin and eosin stain. 
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Figure 16 (page 31). Relative blood hemoglobin concentrations in a long-term primate 
model of acquired hemophilia A. The time courses of blood hemoglobin concentration relative to 
concentration on Day 0 (2 h after cyVIII-2236 injection) are shown as individual values in respective 
cynomolgus monkeys (#1–4) of the vehicle and ACE910 groups. 
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Figure 17 (page 32). Plasma ACE910 concentrations in a long-term primate model of 
acquired hemophilia A. ACE910 was administered at an initial SC dose of 3.97 mg/kg on Day 0 
followed by weekly SC doses of 1 mg/kg on Days 7, 14, 21, 28, 35, 42, and 49. The time courses of 
actual measured and simulated plasma concentrations of ACE910 are shown. The actual measured 
concentrations are presented as individual values for cynomolgus monkeys (#1–4) of the ACE910 group. 
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Figure 18 (page 38). FVIII:C measured in an APTT-based one-stage clotting assay in the 
presence of cyVIII-2236. Data are expressed as means ± SD (n = 3). The bars depicting SD are shorter 
than the height of the symbols. 
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Figure 19 (page 38). Simulated plasma rpoFVIII concentration in a long-term primate 
model of acquired hemophilia A. The simulated course of plasma rpoFVIII concentration is shown 
for a twice-weekly 20 U/kg IV dosing regimen. 
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Figure 20 (page 38). Effects of rpoFVIII on spontaneous bleeds in a long-term primate 
model of acquired hemophilia A. (A) Experimental protocol used for evaluating the preventive 
effects of rpoFVIII in a long-term hemophilia A model induced by the weekly IV dose of 10 mg/kg 
cyVIII-2236. rpoFVIII was administered for 8 weeks on a twice-weekly 20 U/kg IV dosing regimen. (B) 
The time courses of APTT are shown as individual values (#1–4) of the rpoFVIII group. (C) The days in 
which limping was observed are shown in red for the individual cynomolgus monkeys. The number of 
limping days and the number of bleeding joints at necropsy are shown as individual values (#1–4) of the 
rpoFVIII group. (D) The time courses of blood hemoglobin concentration relative to concentration on 
Day 0 (2 h after cyVIII-2236 injection) are shown as individual values (#1–4) of the rpoFVIII group. 
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Figure 21 (page 40). Biological functions of anti-FIXa/FX bispecific antibody, ACE910, as 
a FVIII-cofactor mimetic. In the general conclusions, (i) ACE910 improved coagulation in 
FVIII-deficient plasma both with and without FVIII inhibitors, (ii) a short-term acquired hemophilia A 
model expressing stable artificial bleeds with proper severity was newly established in cynomolgus 
monkeys, and single episodic IV dose of ACE910 significantly inhibited these bleeding symptoms, (iii) 
ACE910 showed the 3-week plasma half-life and high SC bioavailability in cynomolgus monkeys, and 
possibility of effective prophylaxis by the once-weekly SC doses was simulated based on the PK 
parameters, (iv) a long-term acquired hemophilia A model expressing reproducible spontaneous joint 
bleeds and other bleeds was newly established in cynomolgus monkeys, and weekly SC doses of ACE910 
significantly prevented these bleeding symptoms. These results elucidated biological functions of 
ACE910 as a FVIII-cofactor mimetic and suggested that ACE910 has the potential not only to ameliorate 
on-going bleeds, but also to offer a user-friendly and aggressive routine prophylaxis for hemophilia A 
patients both with and without FVIII inhibitors. 
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Biological functions as FVIII-cofactor mimetic
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